Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Pieris Pharmaceuticals (DE:PI60)
FRANKFURT:PI60
Holding DE:PI60?
Track your performance easily
PI60 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€9.92 - €17.56
Previous Close€10.06
Volume0.00
Average Volume (3M)N/A
Market Cap
€20.79M
Enterprise Value-€9.11M
Total Cash (Recent Filing)$44.81M
Total Debt (Recent Filing)$12.29M
Price to Earnings (P/E)―
Beta1.41
Next Earnings
May 08, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,236,688
10 Day Avg. Volume248,800
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)0.41
Price to Sales (P/S)2.13
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.19
Enterprise Value/Gross Profit-0.35
Enterprise Value/Ebitda-0.76
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Pieris Pharmaceuticals News
Options Prices
Currently, No data available
---
Ownership Overview
10.92% Insiders
2.21% Mutual Funds
3.18% Other Institutional Investors
82.85% Public Companies and
Individual Investors
PI60 FAQ
What was Pieris Pharmaceuticals’s price range in the past 12 months?
Pieris Pharmaceuticals lowest stock price was €9.92 and its highest was €17.56 in the past 12 months.
What is Pieris Pharmaceuticals’s market cap?
Currently, no data Available
When is Pieris Pharmaceuticals’s upcoming earnings report date?
Pieris Pharmaceuticals’s upcoming earnings report date is May 08, 2024 which is 189 days ago.
How were Pieris Pharmaceuticals’s earnings last quarter?
Pieris Pharmaceuticals released its earnings results on Mar 27, 2024. The company reported -€3.407 earnings per share for the quarter, beating the consensus estimate of -€8.825 by €5.418.
Is Pieris Pharmaceuticals overvalued?
According to Wall Street analysts Pieris Pharmaceuticals’s price is currently Overvalued.
Does Pieris Pharmaceuticals pay dividends?
Pieris Pharmaceuticals does not currently pay dividends.
What is Pieris Pharmaceuticals’s EPS estimate?
Pieris Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pieris Pharmaceuticals have?
Pieris Pharmaceuticals has 1,324,240 shares outstanding.
What happened to Pieris Pharmaceuticals’s price movement after its last earnings report?
Pieris Pharmaceuticals reported an EPS of -€3.407 in its last earnings report, beating expectations of -€8.825. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Pieris Pharmaceuticals?
Among the largest hedge funds holding Pieris Pharmaceuticals’s share is Platinum Investment Management. It holds Pieris Pharmaceuticals’s shares valued at N/A.
---
Pieris Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-23.97%
12-Months-Change
Fundamentals
Return on Equity
-80.46%
Trailing 12-Months
Asset Growth
-71.38%
Trailing 12-Months
Company Description
Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.
---
PI60 Earnings Call
Q1 2023
0:00 / 0:00
---
Technical Analysis
Pieris Pharmaceuticals
―
Adaptimmune Therapeutics
―
Fate Therapeutics
―
Gritstone bio
―
Eton Pharmaceuticals
―
---